Opendata, web and dolomites

ContiTRACE SIGNED

Continuous Blood Glucose Monitoring and automated therapeutic closed loop medical device for Intensive Care Units

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ContiTRACE project word cloud

Explore the words cloud of the ContiTRACE project. It provides you a very rough idea of what is the project "ContiTRACE" about.

sell    roche    safe    powered    sanofi    inefficient    automated    5th    proves    mortality    pfizer    technique    units    workload    14    business    2022    care    insulin    patients    automatically    consumables    offline    infusion    made    comorbidities    doctors    time    decrease    death    distributors    sensors    trace    public    standardized    levels    infuse    minutes    companies    return    contitrace    estimates    costly    pharma    glucose    17    aventis    big    manual    continuous    adjustments    commercial    limited    human    x10    healthcare    optimize    max    material    private    patient    glycaemic    elektronik    40    caregivers    forecast    icu    informed    regulatory    diagnostica    irregular    discomfort    keep    lifecycle    hospital    body    15    blood    players    intensive    fluctuations    increments    model    intermittent    samples    profits    patented    days    savings    decisions    accesses    manufacturers    calibrating    ai    minimising    twofold    headcounts    bgm    economic    device    company    profil    risk    sasse    300    newcomers    investment    physiological    careful    safety    2026    invasive    penetrate    monitoring    medical    self    icus    50   

Project "ContiTRACE" data sheet

The following table provides information about the project.

Coordinator
TRACE ANALYTICS GMBH 

Organization address
address: RICHARD WAGNER STRASSE 1-2
city: BRAUNSCHWEIG
postcode: 38106
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRACE ANALYTICS GMBH DE (BRAUNSCHWEIG) coordinator 50˙000.00

Map

 Project objective

Intensive Care Units (ICUs) require careful monitoring of blood glucose levels and insulin infusion to keep patients within safe physiological levels. Fluctuations of blood glucose are directly related to an increased risk of death and comorbidities. However, blood glucose monitoring (BGM) is still made by intermittent and manual offline analysis of blood samples. This technique proves inefficient (need 17% caregivers time), costly (€300 per patient) and increments mortality in hospital ICUs by 40% due to irregular glucose level adjustments upon measurements. After 15 years of experience in developing glucose monitoring sensors, we at TRACE are taking on our next big step to penetrate the medical device sector with ContiTRACE: an AI powered automated non-invasive medical device for continuous BGM. Our patented ContiTRACE is able to measure glycaemic levels every 2 minutes (automatically) and automatically infuse insulin when needed. It is also capable of self-calibrating and has standardized body accesses, enhancing safety and minimising discomfort for the ICU patient. This will allow 1) caregivers to decrease their workload, 2) doctors to take informed decisions and 3) the healthcare system to optimize their limited human, economic and material resources by providing savings of more than 50% of BGM related cost. Our business model is twofold. We will sell the medical device (5 years lifecycle), and the consumables (max. 4 days duration per set) to private and public hospital ICUs. Our draft forecast (2022-2026) estimates profits of 14.4 M€ with a Return on Investment of 10.7 by the 5th commercial year allowing us to increase x10 our company headcounts in five commercial years. Although newcomers to the medical sector we have the support of key players among regulatory companies (Profil), manufacturers (Sasse Elektronik), pharma companies (Sanofi-Aventis, Pfizer and Roche) and distributors (Care Diagnostica) to take on the BGM challenge.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONTITRACE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONTITRACE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More